Selenium Protects Retinal Cells from Cisplatin-Induced Alterations in Carbohydrate Residues

Year 2016, Volume: 33 Issue: 4, 441 - 447, 01.07.2016

Dilek Akşit Alper Yazıcı Hasan Akşit Esin S. Sarı Arzu Yay Onur Yıldız Adil Kılıç Sıtkı S. Ermiş Kamil Seyrek

Abstract

Background: Investigate alterations in the expression and localization of carbohydrate units in rat retinal cells exposed to cisplatin toxicity. Aims: The aim of the study was to evaluate putative protective effects of selenium on retinal cells subjected to cisplatin. Study Design: Animal experiment. Methods: Eighteen healthy Wistar rats were divided into three equal groups: 1. Control, 2. Cisplatin and 3. Cisplatin+selenium groups. After anesthesia, the right eye of each rat was enucleated. Results: Histochemically, retinal cells of control groups reacted with α-2,3-bound sialic acid-specific Maackia amurensis lectin (MAA) strongly, while cisplatin reduced the staining intensity for MAA. However, selenium administration alleviated the reducing effect of cisplatin on the binding sites for MAA in retinal cells. The staining intensity for N-acetylgalactosamine (GalNAc residues) specific Griffonia simplicifolia-1 (GSL–1) was relatively slight in control animals and cisplatin reduced this slight staining for GSL-1 further. Selenium administration mitigated the reducing effect of cisplatin on the binding sites for GSL-1. A diffuse staining for N-acetylglucosamine (GlcNAc) specific wheat germ agglutinin (WGA) was observed throughout the retina of the control animals. In particular, cells localized in the inner plexiform and photoreceptor layers are reacted strongly with WGA. Compared to the control animals, binding sites for WGA in the retina of rats given cisplatin were remarkably decreased. However, the retinal cells of rats given selenium reacted strongly with WGA. Conclusion: Cisplatin reduces α-2,3-bound sialic acid, GlcNAc and GalNAc residues in certain retinal cells. However, selenium alleviates the reducing effect of cisplatin on carbohydrate residues in retinal cells.

Keywords

Cisplatin, n-acetylglucosamine, selenium, sialic acid

References

• 1. Carlson BA, Yoo MH, Shrimali RK, Irons R, Gladyshev VN, Hatfield DL, et al. Role of selenium-containing proteins in Tcell and macrophage function. Proc Nutr Soc 2010;69:300-10. [Crossref]
• 2. Zhang ZW, Wang QH, Zhang JL, Li S, Wang XL, Xu SW. Effects of oxidative stress on immunosuppression induced by selenium deficiency in chickens. Biol Trace Elem Res 2012;149:352-61. [Crossref]
• 3. Rayman MP. The importance of selenium to human health. Lancet 2000;356:233-41. [Crossref]
• 4. Puertas MC, Martinez-Martos JM, Cobo MP, Carrera MP, Mayas MD, Ramirez-Exposito MJ. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp Gerontol 2012;47:625-30. [Crossref]
• 5. Thuluvath PJ, Triger DR. Selenium in chronic liver disease. J Hepatol 1992;14:176-82. [Crossref]
• 6. Franz H. Mistletoe lectins and their A and B chains. Oncology 1986;43:23-34. [Crossref]
• 7. Gabius HJ. Tumorlectinologie: Ein gebiet im schnittpunkt von zuckerchemie, biochemie, zellbiologie und onkologie. Angew Chem Int Edit 1988;100:1321-30. [Crossref]
• 8. Argueso P. Glycobiology of the ocular surface: mucins and lectins. Jpn J Ophthalmol 2013;57:150-5. [Crossref]
• 9. Bourrillon R, Aubery M. Cell surface glycoproteins in embryonic development. Int Rev Cytol 1989;116:257-338. [Crossref]
• 10. Summerfield JA. The role of human lectins in host defence. The Linacre Lecture 1991. J Roy Coll Phys Lond 1992;26:92-6.
• 11. Kostrominova TY. Application of WGA lectin staining for visualization of the connective tissue in skeletal muscle, bone, and ligament/tendon studies. Microsc Res Techniq 2011;74:18-22. [Crossref]
• 12. Shin T. The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochem 2013;115:407-11. [Crossref]
• 13. Van der Ende J, Van Baardewijk LJ, Sier CF, Schipper IB. Bone healing and mannose-binding lectin. Int J Surg 2013;11:296- 300. [Crossref
• 14. Amin A, Buratovich MA. New platinum and ruthenium complexes-the latest class of potential chemotherapeutic drugs-a review of recent developments in the field. Mini-Rev Med Chem 2009;9:1489-503. [Crossref]
• 15. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10:795-803.
• 16. Yazici ZM, Meric A, Midi A, Arinc YV, Kahya V, Hafiz G. Reduction of cisplatin ototoxicity in rats by oral administration of pomegranate extract. Eur Arch Oto-Rhino-L 2012;269:45-52. [Crossref]
• 17. Ozbal S, Erbil G, Kocdor H, Tugyan K, Pekcetin C, Ozogul C. The effects of selenium against cerebral ischemia-reperfusion injury in rats. Neurosci Lett 2008;438:265-9. [Crossref]
• 18. Ognjanovi BI, Djordjevic NZ, Matic MM, Obradovic JM, Mladenovic JM, Stajn AS, et al. Lipid peroxidative damage on Cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int J Mol Sci 2012;13:1790-803. [Crossref]
• 19. Rezvanfar MA, Shahverdi AR, Ahmadi A, Baeeri M, Mohammadirad A, Abdollahi M. Protection of cisplatin-induced spermatotoxicity, DNA damage and chromatin abnormality by selenium nanoparticles. Toxicol Appl Pharm 2013;266:356-65. [Crossref]
• 20. Wang PH. Altered sialylation and its roles in gynecologic cancers. J Cancer Mol 2006;2:107-16.
• 21. Roos MD, Hanover JA. Structure of O-linked GlcNAc transferase: mediator of glycan-dependent signaling. Biochem Bioph Res Co 2000;271:275-80. [Crossref]
• 22. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34. [Crossref]
• 23. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. AJP Endocrinology and Metabolism 2008;295:E17-28. [Crossref]
• 24. Yazici A, Sari ES, Yay A, Akşit H, Kilic A, Akşit D, et al. The Protective Effect of Selenium in Cisplatin Related Retinotoxicity. Cutan Ocul Toxicol 2014;33:327-32. [Crossref]
• 25. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer P D 2014;1:18-22. [Crossref]
• 26. Sadeghian S, Kojouri GA, Mohebbi A. Nanoparticles of Selenium as species with stronger physiological effects in sheep in comparison with sodium selenite. Biol Trace Elem Res 2012;146:302-8. [Crossref]
• 27. Bellinger FP, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009;422:11-22. [Crossref]
• 28. Flohe L. Selenium, selenoproteins and vision. In: Nutrition and the eye ed. A, A. Karger; 2005.
• 29. Sheck L, Davies J, Wilson G. Selenium and ocular health in New Zealand. N Z Med J 2010;123:85-94.
• 30. Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN, Bellis SL. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res 2013;6:2-9.